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Relation of cyclic guanosine monophosphate and 
cyclic adenosine monophosphate in reducing the 
toxic effects of protamine administration 
To the Editor: 
We read with great interest he article by Raikar and 
associates 1 regarding nitric oxide inhibition to relieve the 
adverse effects of protamine on blood pressure. They 
declared that hypotension caused by protamine adminis- 
tration can be blocked by nitrous oxide inhibition. We 
would like to add our experience to their information. 
Adverse effects of protamine administration on various 
organ systems have been known for a long time. These 
changes were attributed to the increased complement levels 
associated with an increase in thromboxane and leukotriene 
levels. These mediators may impair the function of organs 
such as the heart and lungs, although these changes are 
mostly clinically insignificant. We 2 documented that leuko- 
triene and thromboxane l vels increased after heparin rever- 
sal with protamine. These changes, which were associated 
with an increase in cyclic guanosine monophosphate 
(cGMP) levels and a reduction in cyclic adenosine mono- 
phosphate (cAMP) levels, adversely affected myocardial 
function. Monitoring cardiac output with a fast-response 
thermistor allowed us to calculate the ejection fraction 
changes in the right ventricle. After protamine administra- 
tion, while right ventricular end-diastolic volume became 
stable, right ventricular end-systolic volume increased signif- 
icantly, indicating the same degree of impairment in myo- 
cardial contractility. However, we did not observe any signif- 
icant change in pulmonary artery pressure. These pressure 
changes were associated with a temporary defect in myocar- 
dial oxidative metabolism, as indicated by the changes in 
myocardial oxygen consumption and myocardial lactate x- 
traction. Prostacyclin usage reduced the toxic mediator e- 
lease and improved myocardial function. After protamin e 
administration, we observed that protamine use decreased 
the cGMP level in the blood and increased the cAMP level 
in the blood. 2' 3 In light of this study, we hypothesized that a 
fall in cAMP level and a rise in cGMP level are responsible 
for the toxic manifestations of heparin reversal with prota- 
mine, similar to our observation during ischemic reperfu- 
sion. 4 On the basis of this information, we used aminophyl- 
line, a phosphodiesterase inhibitor, to increase the cAMP 
level and observed that aminophylline use reduced the toxic 
mediator elease and preserved myocardial function. 5 Fi- 
nally, adverse ffects of protamine on myocardial function 
can be controlled with agents that increase the cAMP levei. 
S. Fehmi Katircio~lu, MD 
O~uz Ta~demir, MD 
Kemal Bayazit, MD 
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Reply to the Editor: 
We appreciate the comments of Dr. Katircio~,lu and his 
colleagues. As noted in their letter, the adverse ffects of 
protamine may be mediated through a variety of mecha- 
nisms, including the complement system. In our study, we 
measured the serum level of cyclic guanosine monophos- 
phate (cGMP) and found no significant change with the 
administration of pr0tamine. Therefore we could not con- 
clude that a fall in the cGMP level correlated with the 
adverse ffects of protamine. This investigation focused on 
inhibition of the nitric oxide pathway, which decreased the 
systemic hypotension produced by protamine administra- 
tion. 
Attempts to attenuate the adverse ffects of protamine 
have met with variable degrees of success. There may be 
several effectors of the systemic effects of protamine, and 
these mechanisms might be expected to cause different 
clinical manifestations during protamine reversal of heparin. 
Goya V. Raikar, MD 
HartzeIl V. Schaff, MD 
Section of Cardiovascular Surgery 
Mayo Clinic 
200 First St. SW 
Rochester, MN 55905 
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Is left ventricular outflow tract obstruction really 
relieved on long-term follow-up? 
To the Editor." 
Luciani and associates I report good results in their 
article titled "One-Stage Repair of Interrupted Aortic 
Arch, Ventricular Septal Defect, and Subaortic Obstruc- 
tion in the Neonate: A Novel Approach." However, I am 
unsure about the long-term results. 
I treated a baby girl, not a neonate, who had a simple 
ventricular septal defect (VSD) associated with infundib- 
ular posterior malalignment, which caused only a 30 mm 
Hg pressure gradient through the left ventricular outflow 
tract (LVOT). Preoperative chocardiographic examina- 
tion showed that she had a large perimembranous VSD 
with a mild pressure gradient between the left ventricle 
and ascending aorta, which resulted from posterior eal- 
alignment of the infundibular septum to the LVOT. 
Cardiac catheterization showed that the right ventricular/ 
left ventricular pressure ratio was 0.9 and the pressure 
gradient through the LVOT was only 30 mm Hg. Cardiac 
angiography also showed that the infundibular septum 
significantly deviated to the LVOT and the ascending 
aorta was relatively small (6 mm). 
The patient was treated with catecholamines for cardiac 
